vai alle Pubblicazioni
Publications prior to 2004
1) Raschi E, De Ponti F. Lubiprostone: pharmacokinetic,
pharmacodynamic, safety and regulatory aspects in the treatment of
constipation-predominant irritable bowel syndrome. Expert Opin.
Drug Metab. Toxicol. 2014;10:293-305. PMID: 24387275
2) Raschi E, Poluzzi E, Godman B, Koci A, Moretti U, Kalaba M,
Bennie M, Barbui C, Wettermark B, Sturkenboom M, De Ponti F. Torsadogenic
risk of antipsychotics: combining adverse event reports with drug
utilization data across Europe.
PLoS One 2013;8:e81208. PMID: 24278396
3) Poluzzi E, Piccinni C, Raschi E, Rampa A, Recanatini M, De
Ponti F. Phytoestrogens
in postmenopause: the state of the art from a chemical,
pharmacological and regulatory perspective. Curr. Med.
Chem. 2014;21:417-36. PMID: 24164197
4) Dothel G, Vasina V, Barbara G, De Ponti F. Animal models of
chemically induced intestinal inflammation: predictivity and
ethical issues. Pharmacol. Ther.;139:71-86. PMID:
23563278
5) Poluzzi E, Raschi E, Koci A, Moretti U, Spina E, Behr ER,
Sturkenboom M, De Ponti F. Antipsychotics and torsadogenicrisk:
signals emerging from the US FDA Adverse Event Reporting System
database. Drug Saf. 2013;36:467-79. PMID: 23553446
6) De Ponti F. Drug development for the irritable bowel
syndrome: current challenges and future perspectives. Front.
Pharmacol. 2013;4:7. doi: 10.3389/fphar.2013.00007. PMID:
23378837
